论文部分内容阅读
In August 2008,racemic tetrabenazine ((±)-3-(2-methylpropyl)-9,10-dimethoxy-1,3,4,6,7,11 b-hexahydro-2H-benzo[a]quinolizin-2-one,(±)-TBZ) was approved for the treatment of chorea associated with Huntingtons disease in USA.The primary pharmacological action of TBZ and its active metabolites is to deplete the levels of monoamines(i.e.dopamine,serotonin,and norepinephrine) within the central nervous system by inhibiting the vesicular monoamine transporter 2(VMAT2).(2R,3R,l lbR)-9-Fluoropropyl-(+)-dihydrotetrabenazine((+)-FP-DTBZ) was found to have nanomolar binding affinity to VMAT2(Ki=6.76 nM).